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Available online 24 February 2016Introduction:NOVAView is a computer aidedﬂuorescencemicroscope that is used for the automated reading and
interpretation of indirect immunoﬂuorescent tests in diagnostic immunology. The objective of the present study
was to evaluate the performance of the NOVA View® system for the measurement of anti-dsDNA antibodies
using the Crithidia luciliae indirect immunoﬂuorescence test (CLIFT) technology.
Methods: Analytical performance of NOVA View CLIFT was assessed in repeatability (within run) and reproduc-
ibility (between runs and instruments) studies. Two hundred-ﬁfty patient samples (N = 200 consecutive sam-
ples and N = 50 samples from systemic lupus erythematosus patients) were tested to evaluate the agreement
between results generated with NOVA View CLIFT, and those obtained with manual microscopic reading of the
same slides. Positivity rate in SLE was assessed on the 50 SLE samples.
Results: TheNOVAView system showedhigh level of repeatability and reproducibilitywithin runs, between runs,
and between instruments. Agreement of NOVA View software interpretation and digital image reading results
with manual microscopic reading results was 96.0%, and the same positivity rate was obtained on SLE samples
by NOVA View digital image reading as that of manual microscopic reading (36.0% vs. 38.0%, respectively).
Conclusion: Results generated by NOVA View CLIFT were equivalent to those obtained by manual microscopic
reading on a large routine sample set. NOVA View demonstrated consistency within and between runs, and be-
tween instruments. Automation of CLIFT provides reliability and is a suitable alternative for routine clinical
laboratories.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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A variety of methods has been developed over the years to measure
antibodies to double stranded (ds)DNA, a key diagnostic marker of sys-
temic lupus erythematosus (SLE). Thesemethods include the Farr assay
(Mahler and Fritzler, 2007), ELISA (Mahler and Fritzler, 2007; Tan et al.,
1982; Aarden et al., 1975a; Fish and Ziff, 1981; Pincus et al., 1969), other
solid phase immunoassays (Infantino et al., 2015; Venner et al., 2013;
Hillebrand et al., 2013; Lemarie et al., 2011), and the Crithidia luciliae
indirect immunoﬂuorescence test (CLIFT) (Somerﬁeld et al., 1981;
Sontheimer and Gilliam, 1978; Stingl et al., 1976). As current solid
phase immunoassays have variable performance due to lack ofs; CLIA, clinical laboratory im-
munoﬂuorescence test; IIF, in-
ematosus; FITC, ﬂuorescein 5-
yrochloride.
Diego, CA 92131, USA.
. This is an open access article understandardization (Chiaro et al., 2011), CLIFT is often regarded as a refer-
ence method, because of its high clinical speciﬁcity (Haugbro et al.,
2004). CLIFT uses the hemoﬂagellate, C. luciliae, as the substrate. This
protozoon, a single-cell organism, possesses a largemodiﬁedmitochon-
drion, called kinetoplast, containing a network of circular dsDNA
(Aarden et al., 1975a). This network of dsDNA appears to be free of his-
tones or other mammalian nuclear antigens (Aarden et al., 1975b;
Crowe and Kushner, 1977). Therefore, reactivity against the kinetoplast
is speciﬁc for anti-dsDNA antibodies (Fig. 1).
The indirect immunoﬂuorescence (IIF) procedure, however, is time
consuming andmanual labor intensive, and themicroscopic interpreta-
tion has high intra- and inter-laboratory variability (Copple et al., 2012,
2014; Van et al., 2009; Sack et al., 2009). There is a strong need for auto-
mation of not only CLIFT, but also other IIF assays, to increase efﬁciency
and to improve the consistency of the results. Recently, computer-aided
automated systems have become available for the interpretation of IIF
assays, such as NOVA View (Inova Diagnostics, Inc.), Aklides (Medipan
GmbH), EUROPattern (Euroimmun AG), Zenit G-Sight (Menarini Diag-
nostics), Helios (Aesku) and Image Navigator (ImmunoConcepts), andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The structure of the Crithidia luciliae organism.
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Bossuyt et al., 2013; Bizzaro et al., 2014; Knutter et al., 2012; Mahler
et al., 2014). These systems not only produce results that show
good agreement withmanual reading, but they are also able to lever-
age the technology to add additional value to the traditional IIF assay
results. As an example, one study has found that the system-
generated light intensity measurements taken during antinuclear
antibodies (ANA) test correlated with likelihood for disease, and
has raised the possibility of using this information for patient strati-
ﬁcation (Schouwers et al., 2014). Automated applications are now
available on multiple devices for detecting ANA and anti-
neutrophil cytoplasmic antibodies (ANCA), but publications on the
CLIFT assay are scarce (Buzzulini et al., 2014; Melegari et al., 2012;Fig. 2. Schematic representation of the NOVA View software algorithm for the iSoda et al., 2011; Gerlach et al., 2015). Therefore our goal was to
evaluate the performance of the NOVA View system for the detection
of anti-dsDNA antibodies with the CLIFT method.
NOVA View is a computer controlled automated ﬂuorescence
microscope, utilizing a light-emitting diode (LED) light source, a
dual band DAPI FITC/HC ﬁlter, and a charge coupled device (CCD)
camera to acquire digital images of predetermined areas of IIF
slides. The system uses a dedicated CLIFT reagent kit, containing a
DNA-binding dye, 4′,6-diamidino-2-phenylindole (DAPI), for
counterstaining cell nuclei and other DNA-containing organelles.
Slides are loaded to the instrument in carriers that can accommodate
up to ﬁve slides. Images are taken using a 40× microscope objective.
Kinetoplasts and nuclei are recognized in the DAPI channel by the
use of an adaptive threshold algorithm, and are differentiated from
each other based on size distribution (Fig. 2). To ensure accurate
cell recognition, overlapping regions and artifacts are excluded
based on predeﬁned criteria, like cell size, shape and relation to
neighboring objects. A brightness value (measured as Light Intensity
Units, LIU) is determined for each kinetoplast in the FITC ﬂuores-
cence channel, and the median value is used for sample classiﬁca-
tion. An adaptive capturing strategy (adjusting focus and exposure
time between wells) ensures rapid imaging of the wells. A minimum
of three digital images of three different ﬁelds of view are generated.
The software categorizes results as positive or negative based on a
pre-determined cut-off LIU value, and presents the digital images
for operator conﬁrmation. All digital images are archived for future
review (Fig. 3).maging and interpretation of the Crithidia luciliae immunoﬂuorescent test.
Fig. 3. Representative screen shot of the NOVA View software CLIFT module user interface. An enlarged digital image out of the three pictures that were acquired (shown on the left) is
shown in the middle of the screen (split into 4 quadrants for easier orientation). Any of the three images can be enlarged by clicking on the appropriate picture. At the bottom of the
computer screen, individual images of selected Crithidia organisms (selected by the software) are displayed at larger magniﬁcation for operator review. The Result panel (table in the
upper right corner) displays the Sample information: sample ID, slide ID, dilution, LIU results, and the classiﬁcation as negative or positive.
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2.1. Samples
Altogether 250 serum specimens were used in the method compar-
ison studies. Two hundred of those were prospectively collected rem-
nant serum samples, sent to Exagen Diagnostics (Vista, CA, US) for
anti-dsDNA laboratory testing (referred to as the “routine” sample
set). These samples were de-identiﬁed, and clinical information was
not available. Fifty samples from clinically diagnosed SLE patients
(obtained from commercial sources) were also tested. Additionally, 20
analytically characterized serum samples (with known anti-dsDNA re-
sults as previously determined by the reference manual C. luciliae IIF
method) were provided by Inova Diagnostics for analytical studies.
Testing was performed in the laboratory of Exagen Diagnostics, Inc., a
CLIA-certiﬁed, CAP-accredited commercial laboratory. This study
meets and is in compliance with all ethical standards in medicine, and
informed consent was obtained from patients (when applicable).
2.2. NOVA Lite dsDNA C. luciliae with DAPI kit
All samples were tested by Exagen with the NOVA Lite dsDNA
C. luciliae kit with DAPI (Inova Diagnostics), according to the package
insert. The 12-well NOVA Lite slides are barcoded (Fig. 2) and patient in-
formation can be linked to the slides in appropriate laboratory informa-
tion system (LIS) setting. Stained slides were read with the NOVA View
system, and also interpreted by traditional ﬂuorescence microscope
(Olympus BX41) with a 40× objective (referred to as “manual read-
ing”). NOVA View generated digital images were reviewed by a trainedoperator on the computer screen (referred to as “digital image read-
ing”), and results were conﬁrmed (or revised and conﬁrmed, when ap-
plicable) to generate the ﬁnal result. The same technologist who
reviewed the digital images on NOVA View performed themanual ﬂuo-
rescence microscope reading to exclude between-reader bias. Sample
classiﬁcation and results obtained with the alternative method were
blinded to the operator. CLIFT results of both manual and digital image
reading were graded by reactivity for each sample on a scale of 0–4 ac-
cording to the intensity; 4 = brilliant apple green ﬂuorescence; 3 =
bright apple green ﬂuorescence; 2 = clearly distinguishable positive
ﬂuorescence; 1 = lowest speciﬁc ﬂuorescence that enables the kineto-
plast staining to be clearly differentiated from the background ﬂuores-
cence; 0 = negative. The 50 SLE samples were also tested at Inova
Diagnostics as part of the between-instruments reproducibility study.
2.3. NOVA View system
NOVA View is a computer controlled ﬂuorescence microscope that
automatically acquires digital images of stained IIF slides, presents
them for operator review, and measures the ﬂuorescent light intensity
of the substrate, as the median value of statistically relevant number
of individual kinetoplasts. A minimum of 3 images are taken to ensure
that the operator has representative ﬁelds of view, including a sufﬁcient
number of cells, tomake sound interpretation. The instrumentmay cap-
ture more than 3 images in cases where the ﬁrst three ﬁelds of view of
thewell do not contain the required number of cells. NOVAView instru-
ments are calibrated usingﬂuorescent beads, to achieve uniformperfor-
mance across all instruments. Based on the light intensity cut-off value
that was established by the manufacturer, NOVA View classiﬁes CLIFT
20 G. Lakos et al. / Journal of Immunological Methods 433 (2016) 17–22results as positive (≥120 LIU), indeterminate (60–119 LIU), or negative
(b60 LIU). For all analysis and calculations included in this study, inde-
terminate results were considered negative. A representative
screenshot of the CLIFT software module user interface is shown in
Fig. 3.
2.4. Analytical studies
2.4.1. Repeatability and reproducibility
The repeatability and reproducibility of the results were assessed in
two studies. In the ﬁrst study, imprecision was assessed by testing one
negative, one medium positive, and one high anti-dsDNA positive sam-
ple in triplicates, in ﬁve separate runs, to produce 15 data points per
sample. Repeatability within runs, and reproducibility between runs
were determined for NOVA View software interpretation and digital
image reading. In the second study, twenty characterized samples
with known anti-dsDNA target results (10 positive and 10 negative)
were processed with the NOVA Lite dsDNA C. luciliae kit, in three sepa-
rate runs, and then read with NOVA View. The digital images were
reviewed and interpreted by the operator, and both NOVA View soft-
ware interpretation and digital image interpretation results were com-
pared to the target results. Moreover, results of the three runs were
compared to each other. In both studies, operators were blinded for
the target results of the samples.
2.4.2. Between instrument reproducibility
To assess reproducibility between instruments, the same 50 SLE
samples that were tested in the Exagen laboratory were also run at
the research laboratory of Inova Diagnostics, and NOVA View software
interpretation and operator's digital image interpretation were com-
pared to those obtained by Exagen.
2.5. Comparison with the reference method on patient samples
Manual microscopic reading is considered the reference method for
IIF assays. NOVA View software generated results and operator's digital
image interpretation results of all 250 clinical samples were compared
to those obtained with manual microscopic reading of the same slides.
Additionally, NOVA View software generated results and digital image
reading results were also compared, with digital image reading results
considered as the reference. Results were compared at the individual
sample level to determine agreement. Moreover, the positivity rate for
operator conﬁrmed NOVA View results on the 50 SLE samples was de-
termined, and compared to manual microscopic reading results.
2.6. Statistical analysis
All statistical analyses were performed by Analyse-it® for Excel
method evaluation software (Version 2.30; Analyse-it Software, Ltd.,
Leeds, UK). Cohen's kappa agreement test was carried out to analyze
the agreement between portions, where kappa values between 0.41
and 0.60 were considered moderate agreement, between 0.61 and
0.80 considered substantial agreement, and kappa values greater than
0.8 considered almost perfect agreement (Viera and Garrett, 2005).
3. Results
3.1. Analytical performance
3.1.1. Repeatability and reproducibility
The negative sample tested in triplicate in ﬁve runs produced an av-
erage LIU of 21.3, with a standard deviation (SD) of ±13.6, and all rep-
licates in all runs were negative by both NOVA View software
interpretation and digital image reading results. The low positive sam-
ple produced 152.2 ± 34.2 LIU. Thirteen out of the 15 replicates were
positive, and two were indeterminate according to LIU values, and allreplicates were interpreted as positive by the operator based on the dig-
ital images. The high positive sample yielded 1037.4 ± 176.2 LIU, and
consistently positive results by both interpretation methods. Reactivity
gradeswere 0 for the ﬁrst sample, 1+ for the second sample, and 3+ to
4+ for the third sample according to digital image interpretation.
Results generated by digital image interpretation on the cohort of 20
characterized samples (10 positive and 10 negative)matched the target
results in 19/20 cases in two runs, and in all 20 cases in the third run.
One sample with “negative” target value, produced LIU values in the in-
determinate range in all three runs, andwas interpreted by the operator
as positive in two runs, and as negative in one run based on the digital
images. Accordingly, total agreement for digital image interpretation
was 100% between the ﬁrst and second run, and 95% between the sec-
ond and third and ﬁrst and third run. Nova View software interpretation
showed perfect concordance between the three runs.
3.1.2. Between instruments reproducibility
There was 92.0% (95% CI: 80.8–97.8%) overall agreement between
Exagen's and Inova's software interpretation results on the 50 SLE sam-
ples. The correlation between instruments according to Cohen's kappa
was almost perfect (0.83, 95% CI: 0.66–0.99). The four discrepant sam-
ples were around the cutoff, with LIU values between 59 and 180. The
agreement between digital image reading outcomes was also 92.0%
(95% CI: 80.8–97.8%) with Cohen's kappa of 0.83 (95% CI: 0.68–0.99) be-
tween the two testing sites. This comparison, however, includes not
only between-instruments, but also between slides, slide processing,
and operator variability, as different technologists interpreted the digi-
tal images at the two testing sites.
3.2. Comparison with the reference method on patient samples
Manual microscopic reading is considered the reference method for
IIF assays, therefore both NOVA View generated results and digital
image reading results were compared to those obtained by manual
reading of the same slides. Both sets of outcomes corresponded toman-
ual reading results in 96.0% of the cases (95% CI: 92.8–98.1%) (Table 1).
Moreover, digital image reading results and NOVA View software inter-
pretation matched in 98.4% of the cases (95% CI: 96.0–99.6%), and al-
most perfect correlation was found by kappa statistics (kappa= 0.94)
(Table 1).
The positivity rate in the 50 SLE samples was 19/50 (38.0%) with
manual microscopic reading, and 18/50 (36.0%) by digital image inter-
pretation, coupled with a 90% agreement between the two interpreta-
tion methods (Table 2).
4. Discussion
This study has demonstrated accurate and consistent performance
of NOVA View CLIFT for the detection of dsDNA antibodies, including
high level of agreement with traditional (manual) interpretation, re-
peatability, reproducibility, and between instrument concordances.
CLIFT is considered a speciﬁc and reliable assay for the detection of
anti-dsDNA antibodies, and has been offered by many clinical laborato-
ries worldwide (Somerﬁeld et al., 1981; Sontheimer and Gilliam, 1978;
Stingl et al., 1976). To overcome the variability, subjectivity, and labor
intensiveness of IIF assays, automated systems are increasingly used
for image acquisition and interpretation (Copple et al., 2014; Bossuyt
et al., 2013; Bizzaro et al., 2014; Knutter et al., 2012;Mahler et al., 2014).
This is the ﬁrst comprehensive evaluation of CLIFT testing with an
automated system. Published information in this ﬁeld is scarce, and in-
complete. An Italian group has published two papers on the theoretical
background of their computer aided diagnosis (CAD) application
(Buzzulini et al., 2014; Soda et al., 2011). Their approach is based on
the three-step classiﬁcation of individual cells, individual images and in-
dividual wells. In that study the training set consisted of 342 images
taken on 63 individual wells, and the validation set contained 83 sera.
Table 1
Agreement between manual reading, digital image interpretation, and NOVA View software interpretation of 250 clinical samples.
Interpretation % PPA (95% CI) % NPA (95% CI) % TPA (95% CI) kappa (95% CI)
Manual interpretation vs.
NOVA View interpretation
88.4 (74.9–96.1) 97.6 (94.5–99.2) 96.0 (92.8–98.1) 0.86 (0.77–0.94)
Manual interpretation vs.
Digital image interpretation
90.7 (77.9–97.4) 97.1 (93.8–98.9) 96.0 (92.8–98.1) 0.86 (0.78–0.95)
Digital image interpretation vs.
NOVA View Interpretation
93.3 (81.7–98.6) 99.5 (97.3–100.0) 98.4 (96.0–99.6) 0.94 (0.89–1.00)
PPA = positive percent agreement, NPA= negative percent agreement, TPA = total percent agreement.
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pretation was high, they used different brands of CLIFT substrate for
the training and validation (The Binding Site vs. Inova Diagnostics),
and also different magniﬁcations (25× and 50× vs. 40×), which raises
questions about the outcome. Another small study performed with the
AKLIDES system has shown 91% concordance with visual interpretation
(Melegari et al., 2012), but the number of samples was only 44. The
most recent publication on the EUROPattern-Suite technology included
569 clinical samples and 100 sera fromhealthy donors, and demonstrat-
ed 97.2% agreement with visual interpretation (Gerlach et al., 2015).
The approach of the EUROPattern system to the cut-off, however,
seems problematic, as authors state that the threshold is conﬁgurable.
This raises concerns that instead of eliminating variability, it may con-
tribute to between-laboratory inconsistencies. In comparison, NOVA
View systems are calibrated to provide consistent performance across
instruments, and a permanent cut-off has been established by the man-
ufacturer. Most importantly, though, none of the above-mentioned
studies have compared the software generated results and the visual in-
terpretation of the digital images to the reference method, interpreta-
tion of the slides with traditional ﬂuorescence microscope. Moreover,
none of these papers included repeatability and reproducibility experi-
ments; neither had they demonstrated between-instrument concor-
dance data.
Our study evaluated the performance of the NOVA View system for
the detection of anti-dsDNA antibodies using CLIFT technology. Soft-
ware generated results and digital image interpretationwere compared
to manual microscopic interpretation (reference method) and to each
other. The NOVA View CLIFT software categorizes samples as negative
or positive based on ﬂuorescence light intensity cut-off; however, a
trained operator has to review the acquired digital images, and conﬁrm
(or revise and conﬁrm) the NOVA View generated results. The operator
conﬁrmed result is the ﬁnal result.
Both NOVA View software interpretation and digital image reading
results showed excellent repeatability and reproducibility within runs
and between runs in two separate experiments. Moreover, results ob-
tained with two different instruments at two testing sites showed
92.0% concordance on 50 SLE samples by both software interpretation
and digital image reading. The four discrepant samples had borderline
results. Of note, besides the different instruments, variables in this
study have also included the slides (substrate), the staining, and also
the reading process, as different operators were interpreting the images
at the two locations. The high level of consistency demonstrated by
NOVA View is an important step toward harmonization of autoantibody
testing and improving between-laboratory portability of CLIFT dsDNA
results.Table 2
Contingency table showing agreement between manual and digital image interpretation
of 50 SLE samples.
Digital image interpretation Manual interpretation
Negative samples Positive samples Total
Negative samples 29 3 32
Positive samples 2 16 18
Total 31 19 50The automated reading and interpretation create permanent digital
records of the results, which can be used for training, consultation and
follow-up purposes. The most important characteristic of the system,
however, is that it provides results that are the same as can be achieved
by manual reading of the slides with traditional ﬂuorescence micro-
scope. The high level of concordance (96.0%) between digital image
reading results and the reference method, manual microscopic reading,
provides evidence that NOVA View delivers excellent image quality
and image ﬁdelity. As the operator does not have the opportunity to
“browse” the wells as they would do during manual interpretation,
the fact that NOVA View provides minimum three images of each well
ensures that sufﬁcient size of representative areas of the substrate is
captured.
Although a limited number of SLE samples were included in this
study, the same positivity rate was obtained by digital image reading
as with manual reading (36.0% vs. 38.0%). This result, together with
the 90% agreement between the two interpretation methods demon-
strates the reliability of the NOVA View CLIFT application in routine
laboratory practice. The positivity rate found in these SLE patients by
both methods is in line with the published literature on the sensitivity
of CLIFT assays (ranging from 8 to 50%), where studies have shown
that CLIFT is highly speciﬁc for anti-dsDNA antibodies and the preva-
lence is dependent on the SLE patient cohort (Lemarie et al., 2011;
Sontheimer and Gilliam, 1978; Isenberg et al., 1987).Conﬂict of interest statement
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